Literature DB >> 2817854

In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor.

K Coleman1, D R Griffin, J W Page, P A Upshon.   

Abstract

The penem BRL 42715, C6-(N1-methyl-1,2,3-triazolylmethylene)penem, is a potent inhibitor of a broad range of bacterial beta-lactamases, including the plasmid-mediated TEM, SHV, OXA, and staphylococcal enzymes, as well as the chromosomally mediated enzymes of Bacteroides, Enterobacter, Citrobacter, Serratia, Morganella, Escherichia, Klebsiella, and Proteus species. The concentration of BRL 42715 needed to reduce the initial rate of hydrolysis of most beta-lactamase enzymes by 50% was less than 0.01 micrograms/ml, which was 10- to 100-fold lower than for other beta-lactamase inhibitors. These potent inhibitory activities were reflected in the low concentrations of BRL 42715 needed to potentiate the antibacterial activity of beta-lactamase-susceptible beta-lactams. Concentrations of 0.25 micrograms/ml or less considerably enhanced the activity of amoxicillin against many beta-lactamase-producing strains. The MIC50 (MIC for 50% of strains tested) of amoxicillin for 412 beta-lactamase-producing members of the family Enterobacteriaceae fell from greater than 128 to 2 micrograms/ml in the presence of 1 microgram of BRL 42715 per ml, whereas 5 micrograms of clavulanic acid per ml brought the MIC50 down to 8 micrograms/ml. Among these 412 strains were 73 Citrobacter and Enterobacter strains, and 1 microgram of BRL 42715 per ml reduced the MIC50 of amoxicillin from greater than 128 to 2 micrograms/ml for the 48 cefotaxime-susceptible strains and from greater than 128 to 8 micrograms/ml for the 25 cefotaxime-resistant strains.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2817854      PMCID: PMC172706          DOI: 10.1128/AAC.33.9.1580

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Characterization of beta-lactamases.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

Review 2.  Plasmid-mediated beta-lactamases of Gram-negative bacteria: properties and distribution.

Authors:  M Matthew
Journal:  J Antimicrob Chemother       Date:  1979-07       Impact factor: 5.790

3.  Types of beta-lactamase determined by plasmids in gram-negative bacteria.

Authors:  M Matthew; R W Hedges; J T Smith
Journal:  J Bacteriol       Date:  1979-06       Impact factor: 3.490

Review 4.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

5.  CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization.

Authors:  A R English; J A Retsema; A E Girard; J E Lynch; W E Barth
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

6.  Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

7.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.

Authors:  P A Hunter; K Coleman; J Fisher; D Taylor
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

Review 8.  Antibiotic resistance in pathogenic and producing bacteria, with special reference to beta-lactam antibiotics.

Authors:  H Ogawara
Journal:  Microbiol Rev       Date:  1981-12

9.  Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes.

Authors:  F Yoshimura; H Nikaido
Journal:  J Bacteriol       Date:  1982-11       Impact factor: 3.490

10.  Beta-lactam resistance in clinical isolates of Escherichia coli caused by elevated production of the ampC-mediated chromosomal beta-lactamase.

Authors:  S Bergström; S Normark
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

View more
  25 in total

1.  A novel type of AmpC beta-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia.

Authors:  A Bauernfeind; I Schneider; R Jungwirth; H Sahly; U Ullmann
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 3.  Current antimicrobial therapy of anaerobic infections.

Authors:  C V Sanders; K E Aldridge
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

4.  Kinetic study of interaction between BRL 42715, beta-lactamases, and D-alanyl-D-alanine peptidases.

Authors:  A Matagne; P Ledent; D Monnaie; A Felici; M Jamin; X Raquet; M Galleni; D Klein; I François; J M Frère
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 5.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

6.  Novel carbapenem-hydrolyzing oxacillinase OXA-62 from Pandoraea pnomenusa.

Authors:  Ines Schneider; Anne Marie Queenan; Adolf Bauernfeind
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 7.  Evolution of beta-lactamase inhibitors.

Authors:  D M Livermore
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

8.  Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.

Authors:  D J Payne; R Cramp; D J Winstanley; D J Knowles
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Partial characterization of Nocardia farcinica beta-lactamases.

Authors:  V A Steingrube; R J Wallace; B A Brown; Y Zhang; L C Steele; G Young; D R Nash
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

10.  Pharmacokinetic studies and renal dehydropeptidase stability of the new beta-lactamase inhibitor BRL 42715 in animals.

Authors:  K Coleman; D R Griffin; P A Upshon
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.